RE: Interesting - Al Musella24 Nov 2025 11:37
If I am reading it correctly it says he will be now more involved in the company. He hasn’t said he will no longer deal with the company, so that’s positive. Is it easier to speak to their organisations as a medical advisor rather than as a director of the company? No update on the current state of the possible legislation. As always as clear as mud.
We keep getting little snippets in RNS’s but nothing about revenue or the trial results. We know the data must be submitted by February so they must be close to having at least a draft copy that could be peer reviewed. The conference networking would have been a good place to discuss this. However, it would have to be JC or CC not KS doing the talking as otherwise would we get a conflict of interest situation?
Thanks